Estetrol prevents Western diet-induced obesity and atheroma independently of hepatic estrogen receptor α.


Journal

American journal of physiology. Endocrinology and metabolism
ISSN: 1522-1555
Titre abrégé: Am J Physiol Endocrinol Metab
Pays: United States
ID NLM: 100901226

Informations de publication

Date de publication:
01 01 2021
Historique:
pubmed: 3 11 2020
medline: 9 2 2021
entrez: 2 11 2020
Statut: ppublish

Résumé

Estetrol (E4), a natural estrogen synthesized by the human fetal liver, is currently evaluated in phase III clinical studies as a new menopause hormone therapy. Indeed, E4 significantly improves vasomotor and genito-urinary menopausal symptoms and prevents bone demineralization. Compared with other estrogens, E4 was found to have limited effects on coagulation factors in the liver of women allowing to expect less thrombotic events. To fully delineate its clinical potential, the aim of this study was to assess the effect of E4 on metabolic disorders. Here, we studied the pathophysiological consequences of a Western diet (42% kcal fat, 0.2% cholesterol) in ovariectomized female mice under chronic E4 treatment. We showed that E4 reduces body weight gain and improves glucose tolerance in both C57Bl/6 and

Identifiants

pubmed: 33135461
doi: 10.1152/ajpendo.00211.2020
doi:

Substances chimiques

Estrogen Receptor alpha 0
Lipids 0
Receptors, LDL 0
Estetrol ENB39R14VF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

E19-E29

Auteurs

Mélissa Buscato (M)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Morgane Davezac (M)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Rana Zahreddine (R)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Marine Adlanmerini (M)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Raphaël Métivier (R)

CNRS, Univ Rennes, IGDR (Institut de Génétique De Rennes), Rennes, France.

Marianne Fillet (M)

Laboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, Quartier Hôpital, Liege, Belgium.

Gael Cobraiville (G)

Laboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, Quartier Hôpital, Liege, Belgium.

Cedric Moro (C)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Jean-Michel Foidart (JM)

Groupe Interdisciplinaire de Génoprotéomique Appliquée, Université de Liège, Liège, Belgique.

Françoise Lenfant (F)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Pierre Gourdy (P)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.
Département de Diabétologie, Maladies Métaboliques et Nutrition, CHU de Toulouse, Toulouse, France.

Jean-François Arnal (JF)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Coralie Fontaine (C)

I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH